How should a 15-year-old female with heavy menstrual bleeding and clots be evaluated and managed?

Evaluation and Management of Heavy Menstrual Bleeding with Clots in a 15-Year-Old

This adolescent requires immediate screening for an underlying bleeding disorder, assessment of hemodynamic stability and anemia, and initiation of medical management—with combined hormonal contraceptives or tranexamic acid as first-line therapy.

Initial Assessment Priority

The presence of clots in a 15-year-old signals potentially heavy menstrual bleeding (HMB) that warrants urgent evaluation. Screen immediately for bleeding disorders, as von Willebrand disease and platelet disorders occur in up to 20% of adolescents with HMB from menarche 1, 2. This is critical because identifying a coagulopathy fundamentally changes management and has implications for future surgeries and quality of life.

Key History Elements to Obtain

Ask specifically about:

• Menstrual duration >7 days
• Soaking >5 pads/tampons per day or requiring nighttime changes
• Passage of clots larger than a quarter
• Bleeding that interferes with school, sports, or social activities
• Family history of bleeding disorders, heavy menses, or excessive bleeding with surgery/dental work
• Personal history of easy bruising, nosebleeds >10 minutes, or bleeding with procedures 2, 3

Immediate Physical Examination

Check orthostatic vital signs (blood pressure and pulse lying and standing) to assess hemodynamic stability 2. This determines whether outpatient management is safe or if hospitalization is needed.

Laboratory Evaluation

Order the following tests at the initial visit:

Essential labs:

• Complete blood count (hemoglobin/hematocrit)
• Serum ferritin (not just hemoglobin—iron deficiency occurs before anemia develops) 2, 3
• Pregnancy test (beta-hCG)
• TSH and prolactin (to rule out endocrine causes of anovulation) 4

Bleeding disorder workup (if any red flags present):

• von Willebrand factor antigen, activity, and factor VIII
• Platelet function testing or PFA-100
• PT/PTT, fibrinogen 1, 2

Common pitfall: Many providers only check hemoglobin and miss iron deficiency. Ferritin <15 ng/mL indicates iron deficiency even with normal hemoglobin, and this requires treatment 3, 5.

First-Line Medical Management

For Hemodynamically Stable Patients

Combined hormonal contraceptives (CHCs) are first-line therapy for adolescents with HMB 1, 2. Options include:

• Oral contraceptive pills (monophasic formulations preferred)
• Contraceptive patch
• Vaginal ring

Alternative first-line option: Tranexamic acid (antifibrinolytic)

• Dose: 1300 mg three times daily during menses only
• Use if CHCs are contraindicated or patient/family prefers non-hormonal therapy 2
• Can be combined with CHCs for severe bleeding 2

NSAIDs (ibuprofen or naproxen) reduce menstrual blood loss by 20-50% and should be used during menses 6. Dose: Ibuprofen 600-800 mg three times daily with food.

For Acute Heavy Bleeding Requiring Hospitalization

If the patient is hemodynamically unstable or has severe anemia (hemoglobin <7 g/dL):

1. High-dose oral CHCs: Monophasic pill containing 30-35 mcg ethinyl estradiol, one pill three times daily until bleeding stops (usually 24-48 hours), then taper 2
2. Intravenous conjugated estrogen: 25 mg every 4-6 hours (maximum 6 doses) if oral therapy fails or patient cannot tolerate oral medications 2
3. Tranexamic acid: Can be given IV (10 mg/kg every 8 hours) or orally 2

Transfusion threshold: Consider packed red blood cells if hemoglobin <7 g/dL or patient is symptomatic 2

Long-Term Maintenance Therapy

After acute bleeding is controlled, transition to maintenance therapy:

Levonorgestrel-releasing intrauterine device (52 mg LNG-IUD) is superior to all other options for reducing menstrual blood loss and is safe and effective in adolescents, including those who have never been pregnant 1, 7. This should be strongly considered, especially if a bleeding disorder is diagnosed.

Other maintenance options:

• Continuous or extended-cycle CHCs (to reduce frequency of menses)
• Oral progestins (medroxyprogesterone acetate or norethindrone)
• Depot medroxyprogesterone acetate injections 2

Iron Replacement

All adolescents with HMB need iron assessment and likely supplementation 3, 5:

• Oral iron: 60-200 mg elemental iron daily (ferrous sulfate 325 mg = 65 mg elemental iron)
• Take with vitamin C to enhance absorption; separate from calcium
• Intravenous iron: Consider if ferritin <15 ng/mL with hemoglobin <10 g/dL, or if oral iron not tolerated or ineffective 5

When to Refer

Refer to hematology if:

• Positive bleeding disorder screening tests
• Failure to respond to first-line hormonal therapy
• Severe anemia requiring transfusion
• Strong family history of bleeding disorders 1, 2

Refer to gynecology if:

• Structural abnormalities suspected (rare in adolescents)
• Failure of medical management
• Need for LNG-IUD placement 2

Critical Considerations for Adolescents

Anovulation from hypothalamic-pituitary-ovarian axis immaturity is the most common cause of HMB in the first 1-2 years post-menarche 8. However, do not assume this is the only cause—bleeding disorders are significantly more common in adolescents with HMB than previously recognized 1, 2.

Quality of life impact: HMB causes school absences, limits participation in sports and social activities, and leads to anxiety. Prompt, effective treatment dramatically improves adolescent well-being 1.

Avoid surgical interventions: Endometrial ablation and hysterectomy are contraindicated in adolescents. Medical management is almost always successful 2, 7.